可选产品分析
经您允许,我们会使用注重隐私的有限分析来了解哪些研究流程有效。我们不会使用广告跟踪器或会话录制。您可以在偏好设置中更改此选择。请阅读 隐私政策.
Exact Sciences Corp's published Hold conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $20.0B | |
|---|---|---|
| P/E (forward) | 55.2x |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | Trend |
|---|---|---|---|---|---|
| Period | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $2.08B | $2.50B | $2.76B | $3.25B | +15.9% |
| Gross profit | $1.42B | $1.76B | $1.92B | $2.26B | +16.7% |
| Operating income | $-618.7M | $-177.3M | $-1.00B | $-169.1M | — |
| Net income | $-623.5M | $-204.1M | $-1.03B | $-207.9M | — |
| EPS (diluted) | $-3.54 | $-1.13 | $-5.59 | $-1.10 | — |
| EBITDA | $-421.1M | $29.3M | $-789.3M | $52.4M | — |
| R&D | $394.2M | $426.9M | $431.2M | $523.0M | +9.9% |
| SG&A | $1.59B | $1.63B | $1.68B | $1.94B | +6.8% |
Recent company headlines from major financial publishers.
Successful Cologuard Plus launch and multi-cancer test expansion drive sustained double-digit growth, scaling margins and expanding terminal multiples.
Continued ~12% revenue growth scaling into strong 70% gross margins. Steady progression toward operating profitability without major multiple compression.
| Ke ↓ / g → | 2.0% | 2.5% | 3.0% | 3.5% | 4.0% |
|---|---|---|---|---|---|
| 7.9% | $144 | $157 | $173 | $193 | $216 |
| 8.9% | $123 | $133 | $144 | $157 | $173 |
| 9.9% | $108 | $115 | $123 | $133 | $144 |
| 10.9% | $95.8 | $101 | $108 | $115 | $123 |
| 11.9% | $86.1 | $90.7 | $95.8 | $101 | $108 |
Upcoming earnings date and setup when available.
每月发布的研究版本所给出的评级。评级比较分析日的价格与公允价值,并不记录判断是否正确。
| 年份 | 1月 | 2月 | 3月 | 4月 | 5月 | 6月 | 7月 | 8月 | 9月 | 10月 | 11月 | 12月 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |